BTIG maintains Haemonetics at Buy, raises price target to $142 from $130

Haemonetics (HAE) reported 18% organic plasma revenue growth in Q2, raising its full-year apheresis revenue growth forecast. MedSurg revenue grew 6%, and margins improved slightly. The company plans increased capital expenditures for capacity expansion. HAE reaffirmed mid-single-digit MedSurg growth for fiscal 2027, with new product launches in early stages.

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

Haemonetics (HAE) reported Q2 FY 2027 organic revenue growth of 10% and 8% for the first half. The company expects FY 2027 organic growth of 6%-9% while expanding the CSL Persona PLUS rollout through 2027, according to management.